Home
>
National Drug Code (NDC)
>
Tyzeka
Tyzeka - 0078-0538-15 - (telbivudine)
Drug Information of Tyzeka
| Product NDC: | 0078-0538 |
| Proprietary Name: | Tyzeka |
| Non Proprietary Name: | telbivudine |
| Active Ingredient(s): | 600 mg/1 & nbsp; telbivudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Tyzeka
| Product NDC: | 0078-0538 |
| Labeler Name: | Novartis Pharmaceuticals Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022011 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20061025 |
Package Information of Tyzeka
| Package NDC: | 0078-0538-15 |
| Package Description: | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0538-15) |
NDC Information of Tyzeka
| NDC Code | 0078-0538-15 |
| Proprietary Name | Tyzeka |
| Package Description | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0538-15) |
| Product NDC | 0078-0538 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | telbivudine |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20061025 |
| Marketing Category Name | NDA |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | TELBIVUDINE |
| Strength Number | 600 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
